AU4690596A - Nucleic acid condensing agents with reduced immunogenicity - Google Patents
Nucleic acid condensing agents with reduced immunogenicityInfo
- Publication number
- AU4690596A AU4690596A AU46905/96A AU4690596A AU4690596A AU 4690596 A AU4690596 A AU 4690596A AU 46905/96 A AU46905/96 A AU 46905/96A AU 4690596 A AU4690596 A AU 4690596A AU 4690596 A AU4690596 A AU 4690596A
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- reduced immunogenicity
- condensing agents
- acid condensing
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36678794A | 1994-12-30 | 1994-12-30 | |
| US366787 | 1994-12-30 | ||
| PCT/US1995/017005 WO1996021036A2 (en) | 1994-12-30 | 1995-12-26 | Nucleic acid condensing agents with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4690596A true AU4690596A (en) | 1996-07-24 |
Family
ID=23444497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU46905/96A Withdrawn AU4690596A (en) | 1994-12-30 | 1995-12-26 | Nucleic acid condensing agents with reduced immunogenicity |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4690596A (en) |
| WO (1) | WO1996021036A2 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US7011976B1 (en) | 1997-03-03 | 2006-03-14 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| US7001764B2 (en) * | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
| ATE340259T1 (en) * | 1996-07-16 | 2006-10-15 | Archibald James Mixson | CATIONIC VEHICLE: DNA COMPLEXES AND THEIR USE IN GENE THERAPY |
| GB9623051D0 (en) * | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| DE19649645A1 (en) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Multiple functional ligand system for target cell-specific transfer of nucleotide sequences |
| EP1905837A1 (en) * | 1997-03-03 | 2008-04-02 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| JP2002514074A (en) * | 1997-03-03 | 2002-05-14 | セル ジェネシス,インコーポレイティド | Adenovirus vectors containing heterologous transcriptional regulatory elements and methods of using the same |
| AU745056B2 (en) * | 1997-04-03 | 2002-03-07 | Genzyme Corporation | Polymer-modified viruses |
| US6569426B2 (en) | 1997-04-03 | 2003-05-27 | Genzyme Corporation | Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity |
| US6306993B1 (en) | 1997-05-21 | 2001-10-23 | The Board Of Trustees Of The Leland Stanford, Jr. University | Method and composition for enhancing transport across biological membranes |
| DE19726186A1 (en) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Complexes for the transport of nucleic acid into higher eukaryotic cells |
| AU7987898A (en) * | 1997-06-26 | 1999-01-19 | Albany Medical College | Antigenic modulation of viral particules |
| EP1002103B1 (en) | 1997-08-04 | 2007-10-17 | Cell Genesys, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| EP0963758A3 (en) * | 1998-05-07 | 2000-03-22 | Universiteit Gent | Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
| ATE411049T1 (en) * | 1998-05-20 | 2008-10-15 | Expression Genetics Inc | LACTOSE OR GALACTOSE-POLYETHYLENE GLYCOL-GRABTED POLY-L-LYSINE AS A GENE CARRIER |
| EP1108048A1 (en) * | 1998-08-24 | 2001-06-20 | Genzyme Corporation | Cationic complexes of polymer-modified adenovirus |
| IL142704A0 (en) * | 1998-12-03 | 2002-03-10 | Aventis Pharma Sa | Novel nucleic acid transferring agents, compositions containing them and uses |
| FR2786700B1 (en) * | 1998-12-03 | 2002-12-06 | Aventis Pharma Sa | NOVEL NUCLEIC ACID TRANSFERS, COMPOSITIONS CONTAINING THEM, AND USES THEREOF |
| JP5025059B2 (en) * | 1999-06-25 | 2012-09-12 | クリステン プランク | Formulation for introducing nucleic acid into cells |
| EP1063254A1 (en) * | 1999-06-25 | 2000-12-27 | Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung | Copolymers for the transport of nucleic acids in the cell |
| US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
| CA2381425A1 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| DE10015906B4 (en) * | 2000-03-30 | 2006-09-07 | Ibfb Pharma Gmbh | Directed gene transfer into Thy-1 positive cells |
| US7094810B2 (en) | 2001-06-08 | 2006-08-22 | Labopharm, Inc. | pH-sensitive block copolymers for pharmaceutical compositions |
| US6939564B2 (en) | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
| US7964571B2 (en) | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| US20090042825A1 (en) * | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
| DE102014016901B4 (en) | 2014-09-17 | 2021-08-12 | Friedrich-Schiller-Universität Jena | Process for the production of new dextran derivatives as active ingredient carrier systems and their use |
| CN108350491A (en) | 2015-11-18 | 2018-07-31 | 加利福尼亚太平洋生物科学股份有限公司 | Nucleic acid is loaded on base material |
| CA3046680A1 (en) | 2016-12-19 | 2018-06-28 | Quantum-Si Incorporated | Loading molecules into sample wells for analysis |
| EP3619323A4 (en) | 2017-05-05 | 2021-01-27 | Quantum-si Incorporated | SUBSTRATES WITH MODIFIED SURFACE REACTIVITY AND AGING-INHIBITIVE PROPERTIES IN BIOLOGICAL REACTIONS |
| AU2019205383B8 (en) | 2018-01-08 | 2023-09-28 | Quantum-Si Incorporated | System and methods for electrokinetic loading of sub-micron-scale reaction chambers |
| KR20220079943A (en) | 2019-10-11 | 2022-06-14 | 퀀텀-에스아이 인코포레이티드 | Surface modification in vapor phase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2122325A2 (en) * | 1971-01-20 | 1972-09-01 | Maes Roland | Polynucleic acid/polycationic compounds - for potentiating antiviral vaccines |
| US3725545A (en) * | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
| US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| AU8628291A (en) * | 1990-09-25 | 1992-04-15 | University Of Connecticut, The | Prolonging expression of polynucleotides introduced into a cell |
| WO1992019749A1 (en) * | 1991-05-03 | 1992-11-12 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Targeted delivery of genes encoding cell surface receptors |
| ES2154637T3 (en) * | 1991-05-14 | 2001-04-16 | Univ Connecticut | CONTRIBUTION OF DIRECT GENES THAT CODIFY IMMUNOGENIC PROTEINS. |
| AU681997B2 (en) * | 1991-09-05 | 1997-09-18 | University Of Connecticut, The | Targeted delivery of poly- or oligonucleotides to cells |
| EP0693130A1 (en) * | 1993-04-05 | 1996-01-24 | The University Of Connecticut | Targeted delivery of genes encoding antisense polyribonucleotides |
| DE4418965A1 (en) * | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Transfection of eukaryotic cells with nucleic acid |
-
1995
- 1995-12-26 WO PCT/US1995/017005 patent/WO1996021036A2/en active Application Filing
- 1995-12-26 AU AU46905/96A patent/AU4690596A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996021036A2 (en) | 1996-07-11 |
| WO1996021036A3 (en) | 1996-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4690596A (en) | Nucleic acid condensing agents with reduced immunogenicity | |
| DE69522690D1 (en) | alpha-ketogultaric acid dehydrogenase gene | |
| AU2757897A (en) | Nucleic acid sensor | |
| GB9626637D0 (en) | Percarboxyilic acid solutions | |
| AU6482398A (en) | Sulfonylaminocarboxylic acids | |
| AU2602297A (en) | Thickened acid composition | |
| AU2929495A (en) | Nucleic acid sequence amplification method | |
| AU6591798A (en) | Nucleic acid catalysts | |
| AU1889797A (en) | Nucleic acid sequence detection | |
| AU2623795A (en) | Immunogenic pharmaceuticals | |
| AU1559199A (en) | Isothiazolcarboxylic acid derivatives | |
| AU1364995A (en) | 5-vinyl- and 5-ethinyl-quinolone- carboxylic acids | |
| AU8234898A (en) | Characterising nucleic acid | |
| AU7813698A (en) | Nucleic acid detection | |
| AU5178999A (en) | Nucleic acid delivery | |
| AU5345798A (en) | Fructan-polycarboxylic acid | |
| AU5905094A (en) | Nucleic acid assay procedure | |
| AU6376698A (en) | Improved nucleic acid assays | |
| AU3004695A (en) | Nucleic acid filters | |
| AU2629295A (en) | Trifluoromethylquinolinecarboxylic acid derivative | |
| AU8234798A (en) | Categorising nucleic acid | |
| GB9410170D0 (en) | Nucleic acid | |
| AU5370696A (en) | Egf-targeted nucleic acid delivery | |
| AU5377599A (en) | Nucleic acids | |
| AU3031495A (en) | Tee peg |